Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy
In participants with ATTR-CM, acoramidis reduced the composite of ACM or first CVH vs placebo, with an early effect driven by a reduction in CVH. (Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy [ATTRibute-CM]; NCT03860935).
Authors
- Adam Castaño (ORCID: https://orcid.org/0000-0003-4482-5840)
- Suresh Siddhanti
- Mazen Hanna (ORCID: https://orcid.org/0000-0002-7251-3003)
- Simon Gibbs (ORCID: https://orcid.org/0000-0002-1244-4106)
- Leonid Katz
- Ted Lystig (ORCID: https://orcid.org/0000-0002-4523-0761)
- Mathew S. Maurer (ORCID: https://orcid.org/0000-0001-5400-5008)
- Julian D. Gillmore (ORCID: https://orcid.org/0000-0001-6174-9232)
- Pablo García‐Pavía (ORCID: https://orcid.org/0000-0002-5470-2257)
- Ahmad Masri (ORCID: https://orcid.org/0000-0002-6390-6526)
- Laura Piera Obici (ORCID: https://orcid.org/0000-0001-7468-700X)
- Martha Grogan (ORCID: https://orcid.org/0000-0002-2541-4440)
- Daniel Philip Judge (ORCID: https://orcid.org/0000-0002-3407-0248)
- Francesco Cappelli (ORCID: https://orcid.org/0000-0002-1622-0732)
- Prem Soman (ORCID: https://orcid.org/0000-0003-1425-6536)
- Kevin Michael Alexander (ORCID: https://orcid.org/0000-0003-4024-3691)
- Kenneth W. Mahaffey
- Jean‐François Tamby (ORCID: https://orcid.org/0009-0002-8892-4488)
- Xiaofan Cao
- Jonathan C. Fox (ORCID: https://orcid.org/0000-0002-1250-5239)
Institutions
- Cleveland Clinic (US)
- Mayo Clinic (US)
- Medical University of South Carolina (US)
- Oregon Health & Science University (US)
- Columbia University Irving Medical Center (US)
- Epworth Hospital (AU)
- The Royal Free Hospital (GB)
- Eastern Health (AU)
- Hospital Universitario Puerta de Hierro Majadahonda (ES)
- Azienda Ospedaliero-Universitaria Careggi (IT)
- University of Pittsburgh Medical Center (US)
- BridgeBio (United States) (US)
- Stanford Medicine (US)
- Policlinico San Matteo Fondazione (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Bridge Pharma (United States) (US)
- University College London (GB)
Publication Details
- Journal
- Journal of the American College of Cardiology
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1016/j.jacc.2024.11.042
- Citations
- 32
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 25.79